In vitro effects of the CCR5 inhibitor maraviroc on human T cell function

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 577-586

  Arberas, H ^a,b   Guardo, A C ^a,b   Bargallo M E ^a,b   Maleno, M J ^a,b   Calvo, M ^b,c   Blanco, J L ^b,c   Garcia F ^b,c   Gatell, J M ^b,c   Plana, M ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HIVACAT   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

CCR5 blockade; Chemotaxis; Immunological effects; T cell activation

Indexed keywords

CD38 ANTIGEN; CD69 ANTIGEN; CHEMOATTRACTANT; CHEMOKINE RECEPTOR CCR5; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; MARAVIROC;

ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURFACE; CELL VIABILITY; CHEMOTAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MIGRATION INHIBITION; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTI-HIV AGENTS; ANTIGENS, CD; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYCLOHEXANES; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; RECEPTORS, CCR5; TRIAZOLES;

EID: 84873600564     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks432     Document Type: Article

References (30)

1. Latinovic O, Kuruppu J, Davis C et al. Pharmacotherapy of HIV-1 infection: focus on CCR5 antagonist maraviroc. Clin Med Ther 2009; 1: 1497-510.
2. Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803-13.
3. Funderburg N, Kalinowska M, Eason J et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS ONE 2010; 5: e13188.
4. Stepanyuk O, Chiang TS, Dever LL et al. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS 2009; 23: 1911-3.
5. Pulido I, Machmach K, Romero-Sanchez MC et al. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity. J Infect 2012; 64: 417-23.
6. Vitiello P, Merlini E, Colella E et al. Maraviroc as intensification strategy in immunological non-responder HIV+ patients with virologic success on HAART. In: Abstracts of the Nineteenth Conference on Retroviruses and Opportunistic Infections, Seattle, 2012. Abstract p630, p. 308. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
7. Lederman MM, Penn-Nicholson A, Cho M et al. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006; 296: 815-26.
8. Alkhatib G. The biology of CCR5 and CXCR4. Curr Opin HIV AIDS 2009; 4: 96-103.
9. Molon B, Gri G, Bettella M et al. T cell costimulation by chemokine receptors. Nat Immunol 2005; 6: 465-71.
10. Corbeau P, Reynes J. CCR5 antagonism in HIV infection: ways, effects, and side effects. AIDS 2009; 23: 1931-43.
11. Ajuebor MN, Carey JA, Swain MG. CCR5 in T cell-mediated liver diseases: what's going on? J Immunol 2006; 177: 2039-45.
12. Garcia F, Plana M, Ortiz GM et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15: F29-40.
13. Andrews E, Glue P, Fang J et al. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. Br J Clin Pharmacol 2010; 69: 51-7.
14. Saag M, Goodrich J, Fatkenheuer G et al. A double-blind, placebocontrolled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009; 199: 1638-47.
15. Asmuth DM, Goodrich J, Cooper DA et al. CD4+ T-cell restoration after weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010; 54: 394-7.
16. Plana M, Garcia F, Gallart T et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 2000; 14: 1921-33.
17. Camargo JF, Quinones MP, Mummidi S et al. CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J Immunol 2009; 182: 171-82.
18. Reeves JD, Gallo SA, Ahmad N et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA 2002; 99: 16249-54.
19. Meditz AL, Haas MK, Folkvord JM et al. HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo. J Virol 2011; 85: 10189-200.
20. Deeks SG, Kitchen CM, Liu L et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004; 104: 942-7.
21. Feau S, Arens R, Togher S et al. Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells. Nat Immunol 2011; 12: 908-13.
22. Carroll RG, Riley JL, Levine BL et al. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science 1997; 276: 273-6.
23. Lin YL, Mettling C, Portales P et al. The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5. AIDS 2008; 22: 430-2.
24. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002; 2: 106-15.
25. Rossi R, Lichtner M, De RA et al. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol 2011; 166: 184-90.
26. Dhami H, Fritz CE, Gankin B et al. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies. J Clin Pharm Ther 2009; 34: 147-60.
27. Fischereder M, Luckow B, Hocher B et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357: 1758-61.
28. Saxena A, Panigrahi A, Gupta S et al. Frequency of T cell expressing Th1 and Th2 associated chemokine receptor in patients with renal allograft dysfunction. Transplant Proc 2012; 44: 290-5.
29. Ribeiro S, Horuk R. The clinical potential of chemokine receptor antagonists. Pharmacol Ther 2005; 107: 44-58.
30. Espiau M, Soler-Palacin P, Paredes R et al. Maraviroc intensification for suboptimal CD4 T cell response in a perinatally HIV-infected adolescent. AIDS 2011; 25: 1243-4.